“Growing Applications of Liquid Biopsy In Non-Invasive Diagnostics”
- Liquid biopsy, which analyzes circulating nucleic acids (DNA, RNA, exosomes) in bodily fluids such as blood, enables early detection, monitoring, and personalized treatment of various diseases, particularly cancer.
- The complexity of extracting high-quality nucleic acids from these diverse and often fragmented samples requires advanced isolation and purification technologies
- For instance, Liquid biopsy, combined with high-throughput omics technologies, is transforming disease management through non-invasive, personalized diagnostics. Expanding use across diverse biofluids and integration into clinical practice highlight its growing utility. Standardization, improved protocols, and biomarker discovery are driving nucleic acid purification advancements, enabling more accurate, accessible, and individualized patient care
- The rise of liquid biopsy as a non-invasive diagnostic tool offers significant opportunities for the nucleic acid isolation and purification market.
- As liquid biopsy is increasingly used for early disease detection and treatment monitoring, there is a growing need for advanced purification technologies capable of extracting high-quality nucleic acids from complex biological fluids.
